ASMB (Assembly Biosciences, Inc)
Insider Trading Activity
Every open-market purchase and sale reported by ASMB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-18 | Jeanette M Bjorkquist | PFO and PAO | Sell | — | — |
| 2026-06-05 | Gina Consylman | Director | A | — | — |
| 2026-06-05 | ANTHONY E ALTIG | Director | A | — | — |
| 2026-06-05 | Susan Mahony | Director | A | — | — |
| 2026-06-05 | Jeanette M Bjorkquist | PFO and PAO | A | — | — |
| 2026-06-05 | William E Delaney IV | Chief Scientific Officer | A | — | — |
| 2026-06-05 | John G McHutchison | Director | A | — | — |
| 2026-06-05 | Nicole S White | Chief Manufacturing Officer | A | — | — |
| 2026-06-05 | Michael Houghton | Director | A | — | — |
| 2026-06-05 | Jason A Okazaki | CEO and President | A | — | — |
| 2026-06-05 | Lisa Johnson-Pratt | Director | A | — | — |
| 2026-06-05 | Anuj Gaggar | Chief Medical Officer | A | — | — |
| 2026-05-27 | GILEAD SCIENCES, INC. | 10%+ Owner | A | — | — |
| 2025-10-03 | GILEAD SCIENCES, INC. | 10%+ Owner | Buy | — | — |
| 2025-06-17 | Jeanette M Bjorkquist | PFO and PAO | A | — | — |
| 2025-06-09 | Gina Consylman | Director | A | — | — |
| 2025-06-09 | Michael Houghton | Director | A | — | — |
| 2025-06-09 | Susan Mahony | Director | A | — | — |
| 2025-06-09 | Lisa Johnson-Pratt | Director | A | — | — |
| 2025-06-09 | John G McHutchison | Director | A | — | — |
| 2025-06-09 | WILLIAM R RINGO | Director | A | — | — |
| 2025-06-09 | ANTHONY E ALTIG | Director | A | — | — |
| 2025-04-15 | John G McHutchison | Director | Sell | — | — |
| 2025-04-01 | Jason A Okazaki | CEO and President | Sell | — | — |
| 2025-04-01 | Anuj Gaggar | Chief Medical Officer | A | — | — |
| 2025-04-01 | Jeanette M Bjorkquist | Principal Accounting Officer | MIXED | — | — |
| 2025-04-01 | Nicole S White | Chief Manufacturing Officer | Sell | — | — |
| 2025-04-01 | William E Delaney IV | Chief Scientific Officer | A | — | — |
| 2024-12-31 | Michael Houghton | Director | Buy | — | — |
| 2024-12-23 | GILEAD SCIENCES, INC. | 10%+ Owner | Buy | — | — |
| 2024-11-26 | Alexander Schornstein | 10%+ Owner | Buy | — | — |
| 2024-11-19 | Nicole S White | Chief Manufacturing Officer | Sell | — | — |
| 2024-10-09 | Alexander Schornstein | 10%+ Owner | Buy | — | — |
| 2024-10-04 | Nicole S White | Chief Manufacturing Officer | Sell | — | — |
| 2024-10-04 | Jason A Okazaki | CEO and President | Sell | — | — |
| 2024-08-05 | Nicole S White | Chief Manufacturing Officer | Sell | — | — |
| 2024-08-05 | Jason A Okazaki | CEO and President | Sell | — | — |
| 2024-07-08 | Alexander Schornstein | 10%+ Owner | Buy | — | — |
| 2024-06-20 | GILEAD SCIENCES, INC. | 10%+ Owner | Buy | — | — |
| 2024-05-30 | Gina Consylman | Director | A | — | — |
| 2024-05-30 | Michael Houghton | Director | A | — | — |
| 2024-05-30 | WILLIAM R RINGO | Director | A | — | — |
| 2024-05-30 | ANTHONY E ALTIG | Director | A | — | — |
| 2024-05-30 | John G McHutchison | Director | A | — | — |
| 2024-05-30 | Lisa Johnson-Pratt | Director | A | — | — |
| 2024-05-30 | Susan Mahony | Director | A | — | — |
| 2024-05-24 | Nicole S White | Chief Manufacturing Officer | Sell | — | — |
| 2024-05-24 | Jason A Okazaki | CEO and President | Sell | — | — |
| 2024-05-24 | John G McHutchison | Director | Sell | — | — |
| 2024-05-24 | Jeanette M Bjorkquist | Principal Accounting Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,977,089 | — |
| — | 10%+ Owner | 720,137 | — |
| — | CEO and President | 163,354 | — |
| — | 10%+ Owner | 110,084 | — |
| — | CEO and President | 69,066 | — |
| — | Chief Scientific Officer | 60,330 | — |
| — | Chief Medical Officer | 52,697 | — |
| — | Chief Manufacturing Officer | 48,145 | — |
| — | Chief Medical Officer | 42,688 | — |
| — | Director | 26,603 | — |
| — | Director | 18,347 | — |
| — | PFO and PAO | 14,560 | — |
| — | EVP & CSO, Virology Ops | 12,068 | — |
| — | See Remarks | 9,792 | — |
| — | Chief Financial Officer | 6,436 | — |
| — | CFO | 4,553 | — |
| — | Chief Medical Officer | 3,446 | — |
| — | Director | 3,202 | — |
| — | SVP-CSO Microbiome | 3,114 | — |
| — | Chief Executive Officer | 1,800 | — |
| — | See Remarks | 1,616 | — |
| — | Director | 1,455 | — |
| — | Director | 667 | — |
| — | Chief Development Officer | 312 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ASMB quote page; the site-wide leaderboard is on the insider transactions hub.